



Journal of Clinical and Translational Research

Journal homepage: <http://www.jctres.com/en/home>

ORIGINAL ARTICLE

FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease

Kiran V.K. Koelfat¹, Ruben G.J. Visschers¹, Caroline M.J.M. Hodin¹, D. Rudi de Waart², Wim G. van Gemert¹, Jack P.M. Cleutjens³, Marion J. Gijbels^{3,4}, Ronit Shiri-Sverdllov⁵, Rajeshwar P. Mookerjee⁶, Kaatje Lenaerts¹, Frank G. Schaap^{1,7}, Steven W.M. Olde Damink^{1,7}

¹ Department of Surgery, Maastricht University Medical Center, Maastricht University, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, the Netherlands

² Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, the Netherlands

³ Department of Pathology, Maastricht University Medical Center, Maastricht, the Netherlands

⁴ Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands

⁵ Department of Molecular Genetics, Maastricht University, Maastricht, the Netherlands

⁶ Institute for Liver and Digestive Health, University College London, London, United Kingdom

⁷ Department of Visceral- and Transplantation Surgery, RWTH Aachen University, Germany

ARTICLE INFO

Article history:

Received: June 30, 2017

Revised: September 22, 2017

Accepted: October 15, 2017

Published online: October 15, 2017

Keywords:

intestinal failure
liver disease
enterohepatic cycle
bile salt signaling
FXR
enterocutaneous fistula

ABSTRACT

Background: Intestinal failure-associated liver disease (IFALD) is a clinical challenge. The pathophysiology is multifactorial and remains poorly understood. Disturbed recirculation of bile salts, *e.g.* due to loss of bile via an enterocutaneous fistula, is considered a major contributing factor. We hypothesize that impaired signaling via the bile salt receptor FXR underlies the development of IFALD. The aim of this study was to investigate whether activation of FXR improves liver homeostasis during chronic loss of bile in rats.

Methods: To study consequences of chronic loss of bile, rats underwent external biliary drainage (EBD) or sham surgery for seven days, and the prophylactic potential of the FXR agonist INT-747 was assessed.

Results: EBD for 7 days resulted in liver test abnormalities and histological liver damage. Expression of the intestinal FXR target gene *Fgf15* was undetectable after EBD, and this was accompanied by an anticipated increase in hepatic *Cyp7a1* expression, indicating increased bile salt synthesis. Treatment with INT-747 improved serum biochemistry, reduced loss of bile fluid in drained rats and prevented development of drainage-associated histological liver injury.

Conclusions: EBD results in extensive hepatobiliary injury and cholestasis. These data suggest that FXR activation might be a novel therapy in preventing liver dysfunction in patients with intestinal failure.

Relevance for patients: This study demonstrates that chronic loss of bile causes liver injury in rats. Abrogated recycling of bile salts impairing of enterohepatic bile salt/FXR signaling underlies these pathological changes, as administration of FXR agonist INT747 prevents biliary drainage-induced liver damage. Pharmacological activation of FXR might be a therapeutic strategy to treat disorders accompanied by a perturbed enterohepatic circulation such as intestinal failure-associated liver disease.

List of abbreviations:

Intestinal failure-associated liver disease (IFALD), enterocutaneous fistula (ECF), small heterodimer partner (SHP), fibroblast growth factor (FGF), farnesoid X receptor (FXR), external biliary drainage (EBD), multidrug resistance-associated protein (MRP), monocyte chemotactic protein (MCP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), Lipopolysaccharide-binding protein (LBP)

*Corresponding author:

Steven Olde Damink

Department of Surgery, Maastricht University Medical Center, PO BOX 5800, 6202 AZ Maastricht, the Netherlands

Tel: +31 43 3881463

E-mail: steven.oldedamink@maastrichtuniversity.nl

1. Introduction

Intestinal failure-associated liver disease (IFALD) is a feared complication in 40 to 55% of adult patients with intestinal failure due to e.g. short bowel syndrome or enterocutaneous fistula (ECF) [1]. The clinical spectrum of liver disease in the context of intestinal failure is varied with signs of cholestasis, hepatic steatosis, steatohepatitis and fibrosis [1]. While multiple factors contribute to IFALD development, including intestinal anatomy, septic episodes, nutritional deficiencies and parenteral nutrition, the exact pathophysiology of IFALD remains poorly understood [2].

It has been postulated that loss of enteric fluid from pancreaticobiliary and intestinal secretions, contributes to the development of IFALD [3-5]. Thus far, only a few studies addressed the functional consequences of such loss. Rinsema et al. showed that loss of succus intestinalis in patients with an ECF was associated with development of hepatic damage [5,6]. Reinfusion of intestinal (*viz.* fistula) fluid into the distal small intestine improved liver injury, despite continued parenteral nutrition [5,6]. In particular loss of bile salts, a quantitatively important constituent of enteric fluid, was suggested to contribute to the development of liver injury in patients with an ECF [5]. Reinfusion of intestinal fluid into the distal enteric tract of intestinal failure patients with a high-output double enterostomy, also led to (rapid) recovery of liver test abnormalities [7]. Collectively, these data suggest that an intact entero-hepatic circulation is crucial to maintain liver homeostasis.

Bile salts act as endogenous activating ligands of nuclear and plasma membrane receptors expressed in numerous tissues, but in particular in the small intestine and the liver [8]. The farnesoid x receptor (FXR) is a bile salt-sensing transcription factor that plays a key role in the regulation of bile salt synthesis, lipid and carbohydrate metabolism, and is required for maintaining intestinal integrity and limiting toxic effects of bile salts [8,9]. Furthermore, activated FXR exerts anti-inflammatory actions by inhibition of NF- κ B activity, a central player in inflammatory processes [10].

Previous studies established the role of the gut in regulating bile salt synthesis [11,12]. In the terminal ileum, FXR stimulates the production of the enteric hormone fibroblast growth factor 15 (Fgf15) and its human orthologue FGF19 [13,14]. This ileal-derived hormone represses the hepatic expression of the bile salt-synthetic enzyme, *Cyp7a1*. Studies in several animal models with an obstructed enterohepatic circulation showed that disruption of the FXR-Fgf15 axis was associated with development of (cholestatic) liver injury [15]. The effect of chronic loss of bile fluid on development of liver injury and the therapeutic effect of FXR activation in this setting, has not been addressed yet in an experimental model.

An abrogated entero-hepatic cycle is expected to result in impaired delivery of bile salt ligands to bile salt receptors, in particular FXR that are essential for intestinal and hepatic function. Thus, we hypothesize that loss of bile fluid leads to diminished activation of FXR, dysregulated bile salt homeo-

stasis and compromised hepatic and intestinal integrity, events that could underlie the development of IFALD. The aim of the study was to investigate the effect of FXR agonism (INT-747, a.k.a. obeticholic acid/Ocaliva®) on prevention of entero-hepatic dysfunction in a rat model of IFALD due to continuous loss of bile.

2. Methods

2.1 Animals and Experimental Procedures

Male Sprague Dawley rats (Charles River) weighing 300-350 grams, were housed under controlled environmental conditions in separate cages at the animal housing facility of Maastricht University. Animals had free access to regular chow and water throughout the experiment. The study was approved by the Animal Care Committee of Maastricht University (DEC 2009-170).

After an acclimatization period of one week, external biliary drainage (EBD) was performed essentially as described by Kuipers et al. [16]. In brief, rats were anesthetized with isoflurane, laparotomized, and the common bile duct was exposed and ligated at its distal part. A small incision was made in the duct at approximately 1 cm from the duodenum and a silicone drain (silclear tubing; ID 0.51mm, OD 0.94mm, Mednet GmbH, Germany) was inserted. The drain was attached to the bile duct and tunnelled subcutaneously from the abdomen to the skull. Subsequently, it was connected with a curved metal stent (using an adjusted 21 Gauge hypodermic needle) secured to the skull with fast curing acrylic powder (Simplex Rapid, Kemdent, UK). A second catheter (polyethylene; ID 0.76mm, OD 1.22mm, Smiths Medical, UK) connected the metal stent with a swivel (Instech Laboratories, NL) protected by a metal spring (Instech Laboratories, NL) [16]. The sham procedure followed the same procedure with manipulation of the common bile duct but without ligation, incision and cannulation of the bile duct.

In a pilot experiment, rats underwent continuous EBD for three or seven days to investigate the severity of liver injury. Although inflammation was already apparent after three days, other signs of histological injury and abnormal biochemistry (cholestasis and hepatocellular damage) developed after 7 days of continuous EBD (data not shown). This duration was chosen for the intervention study. Thus, rats underwent EBD for 7 days or were sham-operated ($n = 8$ per group). Immediately after surgery, animals received a daily intraperitoneal dose of the FXR agonist INT-747 (10 mg/kg in vehicle, kindly provided by Intercept Pharmaceuticals) or vehicle alone (corn oil with 5% DMSO). The final dose of INT-747 was administered 24 hrs before sacrifice. Bile production in the drainage groups was determined daily. Unimpeded bile flow was maintained throughout the experiment in all animals in the drainage groups.

All animals were weighed daily, and none of the animals experienced significant weight changes during the course of the experiment (data not shown). Two rats in the vehicle-

treated EBD group died as a result of biliary peritonitis, one rat in the agonist-treated EBD group died as a result of dehydration, and two rats in the vehicle-sham group died because of abdominal wall dehiscence ($n = 1$) or unknown cause ($n = 1$).

At the end of the experiments, rats were anesthetized with isoflurane and sacrificed through aortic puncture between 8:00 and 12:00 AM. Blood was transferred to EDTA tubes and plasma was prepared by centrifugation. Terminal ileum and liver were harvested and portions were snap-frozen or processed for embedding in paraffin. Plasma and tissue specimens were stored at -80°C until analysis.

2.2 Biochemical Analyses

Liver damage was assessed by analysis of plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), GGT, ALP, and total bilirubin (Synchron LX 20 system, Beckman Coulter, NL). Systemic inflammation was evaluated by measuring plasma IL-6 levels using ELISA (R&D Systems, Minneapolis, MN). Plasma levels of the enterocyte damage marker ILBP were determined by ELISA (Hycult Biotech, Uden, The Netherlands) [17]. Serum levels of the acute phase protein lipopolysaccharide-binding protein (LBP) were determined by ELISA (Hycult Biotech, Uden, the Netherlands) [18]. Bile salts were extracted from liver as described previously [19]. Total bile salts in plasma and liver extracts were measured by an enzymatic cycling method using the Total Bile Acids Assay kit (Diazyme, San Diego, CA). Bile salt composition of liver extracts was determined as described previously [20, 21]. Serum 7 α -hydroxy-4-cholesten-3-one (C4, a surrogate marker of CYP7A1 activity) was measured by LC-MS after acetonitrile precipitation as described earlier [22].

2.3 Liver Histology and Morphometric Analysis

After deparaffinization and rehydration, H&E stained liver sections (4 μm thickness) were scored individually on a 0 to 4 scale for inflammation by a blinded pathologist (MJG). Score 0 indicating no inflammation; score 1 indicating minimal periportal inflammation; score 2 indicating mild inflammation (periportal); score 3 indicating moderate periportal and sinusoidal inflammation and score 4 indicating severe periportal and sinusoidal inflammation. Fibrosis was scored on Sirius Red stained sections with score 0 indicating no fibrosis; score 1 indicating mild periportal fibrosis; score 2 indicating moderate periportal fibrosis with minimal sprouting; score 3 indicating severe periportal fibrosis with moderate sprouting and score 4 indicating bridging fibrosis. Bile duct proliferation was examined by morphometric analysis of pan-cytokeratin stained (Dako) liver sections. In brief, cytokeratin-positive cell area ($>5 \mu\text{m}^2$) and total cell area (H&E stained) were determined in 10 random fields (Leica DM3000 microscope, 100x magnification) of each section by supervised analysis of automated image processing (Leica QWin v3 software). Only tangentially cut bile ductules were analyzed.

2.4 Western Blotting

For immunoblot analysis, liver tissue was homogenized in lysis buffer (200 mM NaCl, 10 mM Tris, 5 mM EDTA, 10% glycerol, 1% NP-40, pH 7.5). 20 μg solubilized liver protein was separated by reducing SDS-PAGE and transferred to PVDF membrane. Following blocking of unoccupied binding sites with PBS containing 5% non-fat dry milk powder, membranes were probed with rabbit anti-rat Cyp7a1 (a kind gift of Dr H.M. Princen, TNO, Leiden, The Netherlands) and rabbit anti-mouse β -actin (Sigma) antibodies. Secondary detection consisted of horseradish peroxidase-labelled goat anti-rabbit IgG antibody (Jackson ImmunoResearch Laboratories, Inc.) and immunocomplexes were visualized using enhanced chemiluminescence (Thermo Scientific). Three independent liver homogenates were analyzed per experimental group.

2.5 RNA isolation and Quantitative Polymerase Chain Reaction

Total RNA was extracted from liver or ileal tissue using TRI reagent (Sigma). 750 ng DNase-treated RNA was converted to cDNA (iScript cDNA synthesis kit, Bio-Rad, Hercules, CA). qPCR reactions were conducted in a volume of 20 μl containing cDNA equivalent to 10 ng total RNA, 1x Absolute qPCR SYBR Green Fluorescein Mix (Westburg, The Netherlands) and 150 nM of gene-specific primers (Eurogentec, The Netherlands) (Supplementary Table 1), and were performed in duplicate. Gene expression levels were determined with iQ5 software (Bio-Rad) using a $\Delta\Delta\text{Ct}$ relative quantification model. The geometric mean of the expression levels of two reference genes (*Hprt* and *Rplp0*) was used as normalization factor, and values are graphically presented relative to median expression in sham-operated controls.

2.6 Intestinal permeability

Intestinal permeability was assessed by measuring release of horseradish peroxidase from everted segments of terminal ileum as described previously [17].

2.7 Statistical analysis

For histological analysis, multiple fields per section were scored and averaged per animal. Histological scores were tested for significance with the Fisher's exact test. Effects of EBD or agonist treatment on serum biochemistry, mRNA expression, morphometric parameters, intestinal permeability, enterocyte damage and systemic inflammation were evaluated with the Mann-Whitney U test for unpaired samples. A Bonferroni correction for multiple testing was applied where appropriate. Differences in daily bile production in the drainage groups were tested with repeated measures ANOVA. For visual purposes, data in graphs are presented as means \pm standard error of mean. *P*-values below 0.05 were considered statistically significant. Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc., CA, USA) and

SPSS 22.0 (IBM SPSS Inc, Chicago, Illinois, USA).

3 Results

3.1 Histological liver damage and cholestasis after continuous biliary drainage

Histological examination showed significant hepatic inflammation in the vehicle-treated EBD rats (Figure 1A). EBD was also associated with histological signs of biliary fibrosis (Figure 1B). Moreover, histological evidence for bile ductular proliferation was apparent, indicating injury to the biliary system (Figure 1A&B). Morphometric analysis revealed that the relative ductal area in liver sections was increased in EBD rats receiving vehicle (Figure 1B). Histological signs of inflammation was accompanied by increased hepatic expression of IL-6 in drained animals receiving vehicle ($P = 0.02$, Fig 2B). A trend ($P = 0.065$) towards elevated circulating IL-6 was noted in drained animals receiving vehicle (Fig 2B). EBD resulted in cholestasis as judged from elevated plasma GGT, ALP and bilirubin levels, and suggesting altered hepatobiliary transport of cholephiles (Figure 1C). ALT and AST levels were signifi-

cantly increased in the EBD-vehicle group reflecting hepatocellular damage (Figure 1C).

3.2 Histological liver damage and cholestasis caused by continuous EBD is ameliorated by FXR agonism

The consequences of activation of FXR on drainage-induced liver damage were studied by administration of the potent FXR agonist INT-747 [23]. In contrast to biliary fibrosis, histopathological scores of hepatic inflammation were significantly lower in drained animals receiving INT-747 (Figure 1B). Morphometric analysis showed that the observation of an expanded ductular network after EBD was not counteracted by INT-747 administration in drained animals (Figure 1B). In fact, INT-747 treatment had a similar effect on ductular area in sham-operated animals (Figure 1B). Although treatment with INT-747 showed histological improvements, this was not accompanied by a significant decrease in expression and circulating levels of IL-6 expression. Expression of other NF- κ B target genes, i.e. the p65 NF- κ B subunit and Cox2 was not affected by EBD or INT-747 treatment (Figure 2B).




Figure 1. The effect of EBD on liver histology, liver tests and the effect of FXR agonism. Sham-operated rats (white bars) and rats undergoing external biliary drainage for 7 days (black bars, EBD) received vehicle or the FXR agonist INT-747 ($n = 6-8$ per group). (A) Representative histological images of H&E and CK19 stained liver sections. Note the portal inflammation, increased ductules and dilated cholangiocytes in drained animals receiving vehicle. (B) Histological scoring of inflammation and fibrosis, and morphometric analysis of ductal area. (C) Serum biochemistry of liver damage and cholestatic markers. *a* Indicates a significant effect of drainage in animals receiving vehicle. *b* Denotes a significant effect of INT-747 in drained animals. The significance level is depicted by asterisks; * ($P < 0.05$), ** ($P < 0.01$) and *** ($P < 0.001$).




Figure 2. Effect of FXR agonism on liver histopathology induced by external biliary drainage. Sham-operated rats (white bars) and rats undergoing external biliary drainage for 7 days (black bars, EBD) received vehicle or the FXR agonist INT-747 ($n = 6-8$ per group). (A) Level of hepatic expression of *Mrp2*, *Mrp3* and (B) NF- κ B target genes and IL-6 in the circulation. (C) Intestinal permeability as assessed by horseradish peroxidase translocation in everted ileal segments and circulating levels of the acute phase reactant LBP. *a* Indicates a significant effect of drainage in animals receiving vehicle. *b* Denotes a significant effect of INT-747 in drained animals. *c* Indicates a significant effect of INT-747 in sham-operated animals. The significance level is depicted by asterisks; * ($P < 0.05$) and ** ($P < 0.01$).

Liver test abnormalities were largely (GGT) or even completely (bilirubin, AST, ALT and AP) prevented by INT-747 (Figure 1C). To further investigate the drainage-associated cholestasis, we studied the expression of hepatic biliary transporters. The expression of multidrug resistance-associated protein-2 (*Mrp2*) was decreased after seven days of EBD indicating reduced capacity to secrete glucuronidated bilirubin into bile (Figure 2A). Among its numerous substrates, *Mrp3* secretes bilirubin diglucuronide in the sinusoidal space. The expression of the basolateral efflux pump *Mrp3* was unchanged after 7 days of EBD (Figure 2A). Despite clear effects of FXR agonism on abnormal liver tests, gene expressions of these transporters were not affected (Figure 2A).

3.3 Continuous biliary drainage is associated with increased intestinal permeability and is prevented by FXR agonism

Patients undergoing external biliary drainage develop bacterial overgrowth with bacterial translocation and endotoxemia, which can be prevented by reinfusing bile into the intestinal tract [24]. To further investigate the mechanism of liver injury in this model we explored the effect of chronic biliary drainage on intestinal permeability and presence of circulating LBP. Intestinal permeability, as assessed by translocation of horseradish peroxidase in everted ileal segments, increased after 7 days of EBD (Figure 2C). This was accompanied by elevated serum LBP levels in drained animals (Figure 2C). This could

likely initiate an inflammatory cascade which leads to hepatocellular injury. INT-747 treatment did not affect intestinal permeability in sham-operated animals, but resulted in a reduction of permeability (Figure 2C, $P = 0.005$) in drained animals without affecting circulating LBP (Figure 2C).

3.4 FXR agonism reduces biliary output in drained animals

Reinfusion of externally collected intestinal (*viz.* fistula) fluid back into the intestinal tract was shown to normalize the fistula output in patients with a high-output proximal ECF [6]. To investigate the effect of FXR activation on the biliary output, externally drained bile was collected daily in drained animals for 7 days. In INT-747 treated animals, drain output was reduced from day five onward (Figure 3). The latter suggests that biliary bile salt secretion, the main driving force for generation of bile flow, is reduced following prolonged EBD in INT-747 treated animals.

3.5 Biliary drainage influences intestinal and hepatic FXR signaling and is largely restored by INT-747

FXR activation in this model was associated with improvement of liver test abnormalities, recovery from histological liver injury and reduced biliary fluid output. To study whether these beneficial effects could be attributed to restored bile salt homeostasis, we explored the FXR/Fgf15 axis in this model. Continuous EBD caused a pronounced decrease in intestinal




Figure 3. Effect of FXR agonism on biliary output. Daily production of bile during the course of external biliary drainage. The significance level is depicted by asterisks; $^*(P < 0.05)$.

mRNA expression of fibroblast growth factor 15 (*Fgf15*) and this was accompanied by increased *Cyp7a1* mRNA (Figure 4A) and protein (Figure 4C) expression, and apparent -yet statistically not significant- elevation of serum bile salt levels in drained animals (Figure 4D), indicating impaired repression of

this key bile salt synthetic enzyme by the regulatory intestinal FXR- *Fgf15* axis. Despite increased transcripts of *Cyp7a1* in drained animals, plasma C4 levels were similar in all groups (Figure 4B). Hepatic bile salt levels were not affected by biliary drainage (Figure 4D). In sham-operated animals, INT-747 treatment resulted in reduced hepatic bile salt content (Figure 4D). INT-747 treatment restored intestinal *Fgf15* expression and prevented the induction of *Cyp7a1* mRNA in drained animals (Figure 4A). Nonetheless, *Cyp7a1* protein levels remained elevated in drained animals receiving INT-747 treatment (Figure 4C). Despite the clear effects of INT-747 on serum biochemistry and histological scores in drained animals, and contrary to expectations, FXR agonism had no effect on expression of prototypical FXR target genes in the liver including *Bsep* and *Shp* (Figure 4A). A trend towards reduced hepatic FXR expression was observed in drained animals receiving vehicle ($P = 0.065$), but FXR levels were similar in INT-747 treated groups of animals and their respective vehicle-treated controls ($P = 0.44$) (Figure 4A).




Figure 4. Effect of FXR agonism on drainage-induced FXR dysfunction. Sham-operated rats (white bars/symbols) and rats undergoing external biliary drainage for 7 days (black bars/symbols, EBD) received vehicle or the FXR agonist INT-747 ($n = 6-8$ per group). (A) Hepatic and ileal (only *Fgf15*) expression of genes related to bile salt synthesis and transport. (B) Plasma C4 levels. (C) Representative immunoblot analysis of hepatic *Cyp7a1* protein expression. (D) Total bile salt levels in the circulation and liver. *a* Indicates a significant effect of drainage in animals receiving vehicle. *c* Indicates a significant effect of INT-747 in sham-operated animals. The significance level is depicted by asterisks; $^*(P < 0.05)$, $^{**}(P < 0.01)$ and $^{***}(P < 0.001)$.

4. Discussion

Prolonged loss of bile fluid in patients with intestinal failure is associated with the development of liver disease in the context of intestinal failure [5]. The major finding of the present study is that hepatobiliary damage and cholestasis induced by prolonged external biliary diversion, can be prevented by treatment with an FXR agonist. These findings may be explained by drainage-induced abrogation of FXR signaling resulting in deranged bile salt homeostasis. Cholestasis can give rise to bile salt-inflicted damage to the liver and/or biliary system. FXR agonism appears to re-instate normal feedback regulation of bile salt synthesis via the intestinal FXR/Fgf15 axis.

Prolonged EBD resulted in damage to the liver (ALT and AST elevations) and the biliary compartment (ALP and GGT elevations). Hepatic inflammation may contribute to impaired canalicular transport (hyperbilirubinemia) and development and/or worsening of cholestatic liver injury [25-27]. Hepatocellular and biliary damage triggers a reparative response (*i.e.* ductular reaction) that results in expansion of the biliary network [28, 29]. This is apparent after 7 days of EBD. FXR agonism, postulated to mimic restoration of bile salt signaling in drained animals, prevented most of the above histopathological alterations. Notably, INT-747 reduced inflammation in drained animals. INT-747 treatment also resulted in an enlarged ductular area. This may be due to the direct or indirect (via Fgf15) effects of activated FXR on cholangiocyte proliferation [30]. The apparent enlarged ductular area in sham-operated animals was not accompanied by alterations in inflammatory or fibrotic scores. This observation suggests that additional inflammatory triggers absent in sham-operated animals are present (*e.g.* toxic bile salts, endotoxins and nutritional deficits like essential fatty acid deficiency) in drained animals. Indeed, hepatic *Il-6* expression, a target of the NF- κ B pathway [31], was elevated in drained animals but not detectable in sham-operated animals. FXR is known to negatively regulate the NF- κ B pathway, which is central to hepatic inflammation [32]. Nonetheless, INT-747 did not lower hepatic expression of *Il-6* or other NF- κ B target genes. This may relate to the timing between last dosing of INT-747 and sacrifice, which may explain the general absence of clear transcriptional effects of FXR agonism. Alternatively, FXR agonism may reduce inflammation through NF- κ B independent signaling pathways such as the c-Jun amino-terminal kinase (JNK) signaling pathway [33]. Lack of obvious (long-lasting) transcriptional effects following INT747 administration (once daily as a bolus) appears to be a general pattern in this study, and may relate to the time interval of 12 hrs between last dosing and sacrifice. INT747 is administered in unconjugated form, and like other hydrophobic bile salts, is postulated to follow a nuclear route after uptake by the liver [34]. By activating FXR, nuclear INT747 elicits a transcriptional response that aims to prevent bile salt toxicity, amongst others by promoting bile salt conjugation and accordingly aqueous solubility. INT747 is

conjugated prior to secretion in bile and undergoes enterohepatic circulation (predominantly in its conjugated form) in the sham-operated animals with intact biliary anatomy. In subsequent rounds of hepatic transit, conjugated OCA is postulated to follow a non-nuclear route for rapid re-secretion in bile. Transcriptional responses elicited by INT747 in the liver may thus be of limited duration, *i.e.* only during first passage through the liver, in our experimental set-up. Functional consequences of transient FXR activation may persist for a longer period, as reflected in improved inflammatory scores and biliary fluid output (Figure 1B, 4) [34].

What could be the mechanism of EBD-induced liver damage? Failed delivery of activating ligands (*viz.* bile salts) results in inadequate function of intestinal FXR during EBD. This potential mechanism has two functional consequences. Firstly, gut barrier integrity will become compromised as inferred from increased intestinal permeability [35], and secondly, intestinal Fgf15-mediated regulation of bile salt synthesis will be disturbed. Impaired gut barrier function may give rise to translocation of bacteria and/or bacterial products resulting in portal endotoxemia and hepatic inflammation. This may be reflected by elevation of serum LBP, an acute phase reactant, and induction of hepatic *Il-6* expression. Furthermore, inflammatory signaling in the liver may interfere with proper function of tight junctions between hepatocyte couplets or bile duct epithelial cells [36]. Similar to observations in other rat models, disrupted tight junctions can lead to bile regurgitation and inflammatory consequences [37-39]. Among other things, inflammation prevents the nuclear localization of R α [40], an obligate heterodimer partner for many nuclear receptors including FXR. This may underlie reduced hepatic *Mrp2* expression after EBD, with retention of bilirubin evoking a compensatory secretion route via upregulation of *Mrp3*. Disturbed feedback regulation of bile salt synthesis on the other hand, results in enhanced production of bile salts as supported by elevated *Cyp7a1* protein in drained animals. However, circulating C4 levels did not reflect the elevated *Cyp7a1* protein. Although, INT-747 treatment had no significant effects on *Cyp7a1* mRNA/protein expression and levels of bile salts in the circulation and the liver, reduced bile flow suggests that FXR agonism prevents deregulated bile salt synthesis following prolonged EBD. Diminished bile salt synthesis in drained animals receiving INT-747 may result in reduced availability of substrates for Bsep and decreased biliary bile salt secretion. The latter constitutes the main driving force for bile formation.

The inflamed liver may be particularly sensitive to toxic effects of excessive bile salts. Nonetheless, 7 days of biliary diversion did not affect hepatic bile salt content, nor did FXR agonism result in significant lowering of hepatic bile salts in drained animals. FXR controls the composition of the bile salt pool and regulates their conjugation, and accordingly influences toxic potential of bile salt species [41, 42]. Drainage changed the composition of the hepatic bile salt pool towards a more hydrophilic, less toxic pool (data not shown). This is likely due to elevation of *Cyp7a1* and increased synthesis of

primary bile salt species, including tauro- β -muricholate. The hepatoprotective effect of INT-747 in drained animals appears unrelated to lowering of hepatic bile salt content or favorable changes in the composition of the hepatic pool (data not shown). The drainage-induced elevation of *Cyp7a1* is counteracted by INT-747, at least at the transcriptional level. Reduced biliary output in drained animals receiving INT-747 can be interpreted as lowered bile salt synthesis and reduced availability to the canalicular transporters responsible for biliary secretion of these osmotically active molecules. Enhanced bile salt synthesis in drained animals may result in detrimental levels of toxic intermediates, which have been implicated in liver injury in patients with genetic bile salt synthesis defects [43]. Toxic effects of such intermediates may be prevented by FXR agonism, and may contribute to its favorable actions in drained animals.

Additional protection may be conferred by preservation of intestinal integrity, thus, limiting first pass exposure of the liver to dietary and microbial insults. Impaired gut barrier function following EBD is evident from elevation of circulating LBP levels, which is already apparent after three days (data not shown). Thus, translocation of microbial products appears an early event in hepatic injury following EBD. However, INT-747 did not reduce serum LBP levels. Likewise, the reported anti-inflammatory effects of FXR agonism were not apparent from our analysis of hepatic inflammatory genes. Thus, the molecular pathways underlying the hepatoprotective action of INT-747 in drained animals remain elusive.

The pathogenesis of liver disease in patients with intestinal failure has remained largely unknown, with studies mainly focusing on the effect of parenteral nutrition [44-46]. The present study focused on the mechanism of liver damage in a model recapitulating only the loss of bile, with preserved flow of pancreatic juices. An intact entero-hepatic cycle and FXR appear to be crucial in maintaining normal liver function. Agonistic activation of FXR reduced loss of bile and prevented liver damage in animals with an interrupted entero-hepatic cycle. Insights from the present study indicate that FXR agonism may be a possible approach to prevent the development of IFALD. Findings in this study could also be applied to other clinical diseases in which the entero-hepatic cycle is interrupted. For example, patients with ECF develop liver damage as a result of loss of bile fluid [5]. Reinfusion of fluid may be performed but has practical difficulties related to the anatomy of the fistula trajectory. In addition to possibly preventing liver damage, supplementation of INT-747 could also be considered for clinical application to control fistula output in ECF patients. Such an intervention may limit loss of fluid in general, and loss of electrolytes in particular. This may be especially relevant for patients with a fistula output above 1.5 L per day, who will require nutritional supplementation, usually through the parenteral route.

Acknowledgements

Kiran V.K. Koelfat was supported by a grant from The

Netherlands Organization for Scientific Research (NWO 022.003.011). Ruben G.J. Visschers was supported by a grant from the Dutch Organization for Health Research and Development (ZONMW AGIKO nr 920-03-537). The authors are greatly indebted to Celien Vreuls, Veerle Bieghs, Martin Lenicek, Wim Buurman, Paul van Dijk and Rick Havinga for valuable technical assistance and scientific input. The generous gift of INT-747 by David Shapiro and Luciano Adorini of Intercept Pharmaceuticals is gratefully acknowledged.

Disclosures

None of the authors have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

References

- [1] Kelly D. Intestinal failure-associated liver disease: what do we know today? *Gastroenterology*. 2006; 130: 7.
- [2] Gabe SM, Culkun A. Abnormal liver function tests in the parenteral nutrition fed patient. *Frontline Gastroenterology*. 2010; 1.
- [3] Wiles A, Woodward JM. Recent advances in the management of intestinal failure-associated liver disease. *Curr Opin Clin Nutr Metab Care*. 2009; 12: 265-272.
- [4] Visschers RG, Olde Damink SW, Schreurs M, Winkens B, Soeters PB, van Gemert WG. Development of hypertriglyceridemia in patients with enterocutaneous fistulas. *Clin Nutr*. 2009; 2: 313-317.
- [5] Rinsema W, Gouma DJ, von Meyenfeldt MF, Soeters PB. Reinfusion of secretions from high-output proximal stomas or fistulas. *Surg Gynecol Obstet*. 1988; 167: 372-376.
- [6] Wu Y, Ren J, Wang G, Zhou B, Ding C, Gu G, Chen J, Liu S, Li J. Fistuloclysis improves liver function and nutritional status in patients with high-output upper enteric fistula. *Gastroenterol Res Pract*. 2014: 941514.
- [7] Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: A 15-year prospective cohort in a referral centre. *Clin Nutr*. 2017; 36: 593-600.
- [8] Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol*. 2014; 11: 55-67.
- [9] Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut*. 2011; 60: 463-472.
- [10] Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. *Hepatology*. 2008; 48: 1383-1386.
- [11] Inagaki T, Choi M, Moschetta A, Peng L, Cummins C, McDonald J, Luo G, Jones S, Goodwin B, Richardson J, Gerard R, Repa J, Mangelsdorf D, Kliewer S. Fibroblast growth factor 15 functions as an enterohepatic signal to regu-

- late bile acid homeostasis. *Cell metabolism*. 2005; 2: 217- 225.
- [12] Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. *Hepatology*. 2012; 56: 1034-1043.
- [13] Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C, Walters JR. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. *Am J Physiol Gastrointest Liver Physiol*. 2013; 304: G940-948.
- [14] Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab*. 2005; 2: 217-225.
- [15] Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. *Gastroenterology*. 2012; 142: 355-65 e1-4.
- [16] Kuipers F, Havinga R, Bosschieter H, Toorop GP, Hindriks FR, Vonk RJ. Enterohepatic circulation in the rat. *Gastroenterology*. 1985; 88: 403-411.
- [17] de Haan J-J, Lubbers T, Hadfoune Mh, Luyer M, Dejong C, Buurman W, Greve J-WM. Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. *Annals of surgery*. 2008; 248: 842-848.
- [18] Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. *J Exp Med*. 1994; 179: 269-277.
- [19] Degirolamo C, Modica S, Vacca M, Di Tullio G, Morgano A, D'Orazio A, Kannisto K, Parini P, Moschetta A. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. *Hepatology*. 2015; 61: 161-170.
- [20] Kunne C, Acco A, Hohenester S, Duijst S, de Waart DR, Zamanbin A, Oude Elferink RP. Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activity. *Hepatology*. 2013; 57: 1509-1517.
- [21] Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. *J Lipid Res*. 1989; 30: 719-730.
- [22] Lenicek M, Vecka M, Zizalova K, Vitek L. Comparison of simple extraction procedures in liquid chromatography-mass spectrometry based determination of serum 7alpha-hydroxy-4-cholesten-3-one, a surrogate marker of bile acid synthesis. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2016; 1033-1034: 317-320.
- [23] Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM. 6alpha-ethylchenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. *J Med Chem*. 2002; 45: 3569-3572.
- [24] Kamiya S, Nagino M, Kanazawa H, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. The value of bile replacement during external biliary drainage: an analysis of intestinal permeability, integrity, and microflora. *Ann Surg*. 2004; 239: 510-517.
- [25] Bolder U, Ton-Nu H, Schteingart C, Frick E, Hofmann A. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. *Gastroenterology*. 1997; 112: 214-225.
- [26] Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen P, Elferink R. Impaired hepatocanalicular organic anion transport in endotoxemic rats. *The American journal of physiology*. 1995; 269: 34.
- [27] Moseley R, Wang W, Takeda H, Lown K, Shick L, Ananthanarayanan M, Suchy F. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. *The American journal of physiology*. 1996; 271: 46.
- [28] Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. *Dig Dis Sci*. 1993; 38: 1291-1296.
- [29] Kakar S, Batts KP, Poterucha JJ, Burgart LJ. Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. *Mod Pathol*. 2004; 17: 874-878.
- [30] Uriarte I, Fernandez-Barrena M, Monte M, Latasa M, Chang H, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion A, Medina J, Marin J, Berasain C, Prieto J, Avila M. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. *Gut*. 2013; 62: 899-910.
- [31] Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. *Mol Cell Biol*. 1990; 10: 2327-2334.
- [32] Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. *Hepatology*. 2008; 48: 1632-1643.
- [33] Seki E, Schwabe RF. Hepatic inflammation and fibrosis: functional links and key pathways. *Hepatology*. 2015; 61: 1066-1079.
- [34] Hambruch E KO, Kremoser C. On the pharmacology of the Farnesoid X Receptor agonists: give me an "A", like in "acid". *Nucl Recept Res*. 2016; 3: 101207.
- [35] Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A*. 2006; 103: 3920-3925.
- [36] Sheth P, Delos Santos N, Seth A, LaRusso NF, Rao RK. Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. *Am J Physiol Gastrointest Liver Physiol*. 2007; 293: G308-318.
- [37] Anderson JM, Glade JL, Stevenson BR, Boyer JL, Mooseker MS. Hepatic immunohistochemical localization of the tight

- junction protein ZO-1 in rat models of cholestasis. *Am J Pathol.* 1989; 134: 1055-1062.
- [38] Kawaguchi T, Sakisaka S, Sata M, Mori M, Tanikawa K. Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis. *Hepatology.* 1999; 29: 205-216.
- [39] Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. *Hepatology.* 2000; 31: 1285-1295.
- [40] Denson L, Auld K, Schiek D, McClure M, Mangelsdorf D, Karpen S. Interleukin-1 β suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. *The Journal of biological chemistry.* 2000; 275: 8835-8843.
- [41] Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK. Farnesoid X receptor regulates bile acid-amino acid conjugation. *J Biol Chem.* 2003; 278: 27703-27711.
- [42] Pereira-Fantini PM, Lapthorne S, Joyce SA, Dellios NL, Wilson G, Fouhy F, Thomas SL, Scurr M, Hill C, Gahan CG, Cotter PD, Fuller PJ, Hardikar W, Bines JE. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. *J Hepatol.* 2014; 61: 1115-1125.
- [43] Bove KE, Heubi JE, Balistreri WF, Setchell KD. Bile acid synthetic defects and liver disease: a comprehensive review. *Pediatr Dev Pathol.* 2004; 7: 315-334.
- [44] Naini B, Lassman C. Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. *Human pathology.* 2012; 43: 826-833.
- [45] Llop J, Virgili N, Moreno-Villares J, García-Peris P, Serrano T, Forga M, Solanich J, Pita A. Phytosterolemia in parenteral nutrition patients: implications for liver disease development. *Nutrition (Burbank, Los Angeles County, Calif.).* 2008; 24: 1145-1152.
- [46] Jain A, Stoll B, Burrin D, Holst J, Moore D. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. *Am J of Phy. Gastro and Liver Phys.* 2012; 302: 24.